Cargando…
Risk factors of hepatocellular carcinoma in type 2 diabetes patients: A two-centre study in a developing country
Type 2 diabetes mellitus (T2DM) is increasingly known as a risk factor of hepatocellular carcinoma (HCC). In this study, we determined the risk factors associated with HCC in T2DM patients. This was a matched case-control study conducted at two hepatobiliary referral centres in a developing country....
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8659343/ https://www.ncbi.nlm.nih.gov/pubmed/34882716 http://dx.doi.org/10.1371/journal.pone.0260675 |
_version_ | 1784612942641102848 |
---|---|
author | Azit, Noor Atika Sahran, Shahnorbanun Voon Meng, Leow Subramaniam, Manisekar Mokhtar, Suryati Mohammed Nawi, Azmawati |
author_facet | Azit, Noor Atika Sahran, Shahnorbanun Voon Meng, Leow Subramaniam, Manisekar Mokhtar, Suryati Mohammed Nawi, Azmawati |
author_sort | Azit, Noor Atika |
collection | PubMed |
description | Type 2 diabetes mellitus (T2DM) is increasingly known as a risk factor of hepatocellular carcinoma (HCC). In this study, we determined the risk factors associated with HCC in T2DM patients. This was a matched case-control study conducted at two hepatobiliary referral centres in a developing country. Patients’ sociodemographic, clinical, and biochemical characteristics between 1 January 2012 and 30 June 2018 were extracted from the electronic medical records and analysed using multivariate logistic regression analysis. A total of 212 case-control pairs were included. Significant risk factors included Chinese and Malay ethnicities that interacted with viral hepatitis (adjusted odds ratio [AOR] = 11.77, 95% confidence interval [CI]: 1.39–99.79) and (AOR = 37.94, 95% CI: 3.92–367.61) respectively, weight loss (AOR = 5.28, 95% CI: 2.29–12.19), abdominal pain/ discomfort (AOR = 6.73, 95% CI: 3.34–13.34), alcohol (AOR = 4.08, 95% CI: 1.81–9.22), fatty liver (AOR = 3.29, 95% CI: 1.40–7.76), low platelet (AOR = 4.03, 95% CI:1.90–8.55), raised alanine transaminase (AOR = 2.11, 95% CI: 1.16–3.86). and alkaline phosphatase (ALP) levels (AOR = 2.17, 95% CI: 1.17–4.00). Statins reduced the risk of HCC by 63% (AOR = 0.37, 95% CI: 0.21–0.65). The identification of these factors aids the risk stratification for HCC among T2DM patients for early detection and decision-making in patient management in the primary care setting. |
format | Online Article Text |
id | pubmed-8659343 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-86593432021-12-10 Risk factors of hepatocellular carcinoma in type 2 diabetes patients: A two-centre study in a developing country Azit, Noor Atika Sahran, Shahnorbanun Voon Meng, Leow Subramaniam, Manisekar Mokhtar, Suryati Mohammed Nawi, Azmawati PLoS One Research Article Type 2 diabetes mellitus (T2DM) is increasingly known as a risk factor of hepatocellular carcinoma (HCC). In this study, we determined the risk factors associated with HCC in T2DM patients. This was a matched case-control study conducted at two hepatobiliary referral centres in a developing country. Patients’ sociodemographic, clinical, and biochemical characteristics between 1 January 2012 and 30 June 2018 were extracted from the electronic medical records and analysed using multivariate logistic regression analysis. A total of 212 case-control pairs were included. Significant risk factors included Chinese and Malay ethnicities that interacted with viral hepatitis (adjusted odds ratio [AOR] = 11.77, 95% confidence interval [CI]: 1.39–99.79) and (AOR = 37.94, 95% CI: 3.92–367.61) respectively, weight loss (AOR = 5.28, 95% CI: 2.29–12.19), abdominal pain/ discomfort (AOR = 6.73, 95% CI: 3.34–13.34), alcohol (AOR = 4.08, 95% CI: 1.81–9.22), fatty liver (AOR = 3.29, 95% CI: 1.40–7.76), low platelet (AOR = 4.03, 95% CI:1.90–8.55), raised alanine transaminase (AOR = 2.11, 95% CI: 1.16–3.86). and alkaline phosphatase (ALP) levels (AOR = 2.17, 95% CI: 1.17–4.00). Statins reduced the risk of HCC by 63% (AOR = 0.37, 95% CI: 0.21–0.65). The identification of these factors aids the risk stratification for HCC among T2DM patients for early detection and decision-making in patient management in the primary care setting. Public Library of Science 2021-12-09 /pmc/articles/PMC8659343/ /pubmed/34882716 http://dx.doi.org/10.1371/journal.pone.0260675 Text en © 2021 Azit et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Azit, Noor Atika Sahran, Shahnorbanun Voon Meng, Leow Subramaniam, Manisekar Mokhtar, Suryati Mohammed Nawi, Azmawati Risk factors of hepatocellular carcinoma in type 2 diabetes patients: A two-centre study in a developing country |
title | Risk factors of hepatocellular carcinoma in type 2 diabetes patients: A two-centre study in a developing country |
title_full | Risk factors of hepatocellular carcinoma in type 2 diabetes patients: A two-centre study in a developing country |
title_fullStr | Risk factors of hepatocellular carcinoma in type 2 diabetes patients: A two-centre study in a developing country |
title_full_unstemmed | Risk factors of hepatocellular carcinoma in type 2 diabetes patients: A two-centre study in a developing country |
title_short | Risk factors of hepatocellular carcinoma in type 2 diabetes patients: A two-centre study in a developing country |
title_sort | risk factors of hepatocellular carcinoma in type 2 diabetes patients: a two-centre study in a developing country |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8659343/ https://www.ncbi.nlm.nih.gov/pubmed/34882716 http://dx.doi.org/10.1371/journal.pone.0260675 |
work_keys_str_mv | AT azitnooratika riskfactorsofhepatocellularcarcinomaintype2diabetespatientsatwocentrestudyinadevelopingcountry AT sahranshahnorbanun riskfactorsofhepatocellularcarcinomaintype2diabetespatientsatwocentrestudyinadevelopingcountry AT voonmengleow riskfactorsofhepatocellularcarcinomaintype2diabetespatientsatwocentrestudyinadevelopingcountry AT subramaniammanisekar riskfactorsofhepatocellularcarcinomaintype2diabetespatientsatwocentrestudyinadevelopingcountry AT mokhtarsuryati riskfactorsofhepatocellularcarcinomaintype2diabetespatientsatwocentrestudyinadevelopingcountry AT mohammednawiazmawati riskfactorsofhepatocellularcarcinomaintype2diabetespatientsatwocentrestudyinadevelopingcountry |